Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Unlimited Watchlists, Portfolios, Screeners, and other Barchart tools. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Ikena Oncology Inc (IKNA)

Ikena Oncology Inc (IKNA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 128,712
  • Shares Outstanding, K 36,257
  • Annual Sales, $ 30,990 K
  • Annual Income, $ -34,120 K
  • 60-Month Beta 0.75
  • Price/Sales 4.05
  • Price/Cash Flow N/A
  • Price/Book 0.72
Trade IKNA with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/22
See More
  • Average Estimate -0.50
  • Number of Estimates 4
  • High Estimate -0.45
  • Low Estimate -0.56
  • Prior Year -0.40
  • Growth Rate Est. (year over year) -25.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.32 +6.93%
on 09/23/22
5.58 -36.38%
on 09/06/22
-1.24 (-25.89%)
since 08/23/22
3-Month
3.32 +6.93%
on 09/23/22
6.50 -45.38%
on 06/27/22
-0.60 (-14.46%)
since 06/23/22
52-Week
2.83 +25.44%
on 05/02/22
17.50 -79.71%
on 11/15/21
-9.26 (-72.29%)
since 09/23/21

Most Recent Stories

More News
Ikena Oncology, Inc. (IKNA) Reports Q2 Loss, Misses Revenue Estimates

Ikena Oncology, Inc. (IKNA) delivered earnings and revenue surprises of -18.75% and 100%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

IKNA : 3.55 (+2.60%)
FBIO : 0.7850 (-7.21%)
Ikena Oncology Reports Second Quarter 2022 Financial Results and Provides a Corporate Update

Advancement across Company’s pipeline towards regulatory and data milestones...

IKNA : 3.55 (+2.60%)
Ikena Oncology to Participate in the William Blair Biotech Focus Conference 2022

BOSTON, July 06, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in...

IKNA : 3.55 (+2.60%)
Ikena Oncology to Participate in Spring 2022 Investor Conferences

BOSTON, May 18, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in...

IKNA : 3.55 (+2.60%)
The Zacks Analyst Blog Highlights Angion Biomedica, Applied Therapeutics, Bolt Biotherapeutics, Ikena Oncology, and Landos Biopharma

Angion Biomedica, Applied Therapeutics, Bolt Biotherapeutics, Ikena Oncology, and Landos Biopharma are part of Zacks top Analyst Blog

ANGN : 1.0000 (+6.97%)
APLT : 0.9646 (+1.37%)
LABP : 0.6733 (-7.78%)
BOLT : 1.7200 (-1.71%)
IKNA : 3.55 (+2.60%)
Ikena Oncology, Inc. (IKNA) Reports Q1 Loss, Tops Revenue Estimates

Ikena Oncology, Inc. (IKNA) delivered earnings and revenue surprises of -11.90% and 4.57%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

IKNA : 3.55 (+2.60%)
SPRO : 1.9700 (-10.45%)
Ikena Oncology Reports First Quarter 2022 Financial Results and Provides a Corporate Update

IK-175 clinical trial combination expansion cohort in patients with urothelial carcinoma advanced to Stage 2 based on tolerability and preliminary...

IKNA : 3.55 (+2.60%)
Is a Surprise Coming for Ikena Oncology (IKNA) This Earnings Season?

Ikena Oncology (IKNA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

IKNA : 3.55 (+2.60%)
5 Biotech Stocks Set to Outpace Q1 Earnings Estimates

Let us take a look at some drug/biotech stocks, ANGN, APLT, BOLT, IKNA and LABP, which are poised to beat on first-quarter earnings.

ANGN : 1.0000 (+6.97%)
APLT : 0.9646 (+1.37%)
LABP : 0.6733 (-7.78%)
BOLT : 1.7200 (-1.71%)
IKNA : 3.55 (+2.60%)
Seismic Therapeutic Appoints Maude Tessier, PhD, as Chief Business Officer

Seismic Therapeutic, Inc. , a biotechnology company advancing machine learning for immunology drug development, today announced the appointment of Maude Tessier, PhD, as Chief Business Officer. Dr. Tessier...

IKNA : 3.55 (+2.60%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Ikena Oncology Inc. is focused on developing cancer therapies targeting key signaling pathways which drive the formation and spread of cancer. The company's product candidates include IK-930, IK-175, IK-412 and IK-007, which are in clinical stage. Ikena Oncology Inc. is based in Boston, United States....

See More

Key Turning Points

3rd Resistance Point 4.34
2nd Resistance Point 4.09
1st Resistance Point 3.82
Last Price 3.55
1st Support Level 3.30
2nd Support Level 3.05
3rd Support Level 2.78

See More

52-Week High 17.50
Fibonacci 61.8% 11.90
Fibonacci 50% 10.16
Fibonacci 38.2% 8.43
Last Price 3.55
52-Week Low 2.83

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar